Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Sitbon, R. Souza, Z. C. Jing, X. Jaïs, M. Humbert, J. Le Pavec, C. Tcherakian, K. Boutet, G. Simonneau (Clamart, France). Survival in pulmonary arterial hypertension (PAH): impact of 3 different periods of management. Eur Respir J 2007; 30: Suppl. 51, 1593

Member's Comments

No comment yet.

Related content which might interest you: Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Survival effects of pulmonary vasodilators in group 3 pulmonary hypertension Source: Virtual Congress 2021 – Non-pulmonary arterial hypertension pulmonary hypertension Year: 2021 Mobile spiroergometry for prediction of survival in pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 A critical analysis of survival in pulmonary arterial hypertension Source: Eur Respir Rev 2012 21:218-222 Year: 2012 A 1-year evolution of pulmonary artery pressure in the patients treated with various therapeutic methods after acute pulmonary embolism (PE). Its impact on the chronic thromboembolic pulmonary hypertension (CTEPH) development Source: Eur Respir J 2003; 22: Suppl. 45, 221s Year: 2003 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy? Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Impact of initiation of sildenafil on patterns of healthcare utilization and cost in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Improving survival in pulmonary arterial hypertension Source: Eur Respir J 2005; 25: 218-220 Year: 2005 Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Risk stratification in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – New trends in the management of pulmonary hypertension Year: 2018 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Patterns of mean pulmonary artery pressure (mPAP)-flow relation changes following chronic therapy in idiopathic pulmonary arterial hypertension (IPAH) Source: Eur Respir J 2006; 28: Suppl. 50, 427s Year: 2006 Predicting survival in pulmonary arterial hypertension: time to move forward Source: Eur Respir J 2010; 35: 958-959 Year: 2010 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009